ClearPoint Neuro, Inc. (NASDAQ:CLPT) Short Interest Down 11.3% in August

ClearPoint Neuro, Inc. (NASDAQ:CLPT) was the target of a significant drop in short interest in the month of August. As of August 31st, there was short interest totalling 709,400 shares, a drop of 11.3% from the August 15th total of 799,700 shares. Based on an average trading volume of 237,700 shares, the days-to-cover ratio is presently 3.0 days.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the stock. Lake Street Capital raised their target price on shares of ClearPoint Neuro from $11.00 to $15.00 and gave the stock a “buy” rating in a research report on Tuesday, August 27th. B. Riley assumed coverage on shares of ClearPoint Neuro in a research report on Thursday, July 25th. They set a “buy” rating and a $10.00 target price on the stock.

ClearPoint Neuro Stock Down 2.2 %

CLPT stock traded down $0.26 during trading on Wednesday, hitting $11.66. 223,297 shares of the company’s stock traded hands, compared to its average volume of 181,465. The firm has a market capitalization of $319.72 million, a P/E ratio of -13.96 and a beta of 1.12. The business has a fifty day simple moving average of $9.77 and a two-hundred day simple moving average of $7.29. ClearPoint Neuro has a 1 year low of $4.05 and a 1 year high of $13.47.

ClearPoint Neuro (NASDAQ:CLPT) last released its quarterly earnings results on Wednesday, August 7th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.03. ClearPoint Neuro had a negative net margin of 64.06% and a negative return on equity of 64.23%. The business had revenue of $7.86 million for the quarter, compared to analyst estimates of $7.50 million. During the same period in the previous year, the company earned ($0.29) earnings per share. On average, equities research analysts predict that ClearPoint Neuro will post -0.65 EPS for the current fiscal year.

Hedge Funds Weigh In On ClearPoint Neuro

Several institutional investors and hedge funds have recently bought and sold shares of CLPT. Point72 DIFC Ltd acquired a new stake in shares of ClearPoint Neuro during the second quarter worth $32,000. Cubist Systematic Strategies LLC acquired a new stake in shares of ClearPoint Neuro during the second quarter worth $419,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of ClearPoint Neuro during the second quarter worth $175,000. Squarepoint Ops LLC acquired a new stake in shares of ClearPoint Neuro during the second quarter worth $549,000. Finally, Marshall Wace LLP lifted its stake in shares of ClearPoint Neuro by 202.2% during the second quarter. Marshall Wace LLP now owns 58,260 shares of the company’s stock worth $314,000 after buying an additional 38,984 shares during the period. 30.08% of the stock is owned by hedge funds and other institutional investors.

About ClearPoint Neuro

ClearPoint Neuro, Inc operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain.